清肺合剂联合GP方案治疗晚期非小细胞肺癌临床疗效观察

目的:观察清肺合剂联合化疗治疗晚期非小细胞肺癌(NSCLC)临床疗效。方法:选择2008年1月-2010年1月间收治的经确诊的初治晚期NSCLC患者210例,分别入清肺合剂联合GP方案(治疗组)104例和单纯GP方案化疗(对照组)106例,入组患者至少接受2个周期以上的化疗。结果:入组的210例患者均可评价疗效,治疗1年后随访210例,治疗组99例,对照组98例,失访13例。治疗组和对照组总有效率分别是26.92%和19.81%,中位生存期为15.7个月和14.8个月,1年生存率为63.64%和55.10%。两组差异无显著性(P0.05)。治疗后,治疗组在KPS评分、临床症状改善及化疗不良反应方面与对照组比较差异有统计学意义(P0.05)。结论:清肺合剂联合化疗治疗晚期非小细胞肺癌,在改善患者的临床症状,提高患者的生活质量,减轻化疗的不良反应等方面具有临床意义。

Clinical Effects of Qingfei Mixture Combined with Chemotherapy of GP Regimen in Treating Patients with Advanced Non-Small Cell Lung Cancer

Objective: To observe the effects of Qingfei Mixture in association with chemotherapy in curing patients with advanced non-small cell lung cancer(NSCLC).Methods:Two hundreds and ten patients with confimed diagnosis of advanced non-small cell lung cancer between January 2008 and January 2010,were assigned to treatment group(Qingfei Mixture treatment combined with chemotherepy of GP regimen,n=104)and control group(chemotherepy of GP regimen,n=106).All eligible patients received two cycles chemotherapy at least.Results:210 patients were evaluated for efficacy.The effective rate was 26.92% vs 19.81% in the treatment group and the control group respectively,median overal survival(OS)was 15.7months vs 14.8months,1-year survival was 63.64% vs 55.10%,but there were no significant differences between two groups(P>0.05).However,the KPS score,clinical symptom improvement and chemotherapy toxicity in the treatment group had statistical significance differences compared with those in the control group(P<0.05).Conclusion:Qingfei Mixture can improve clinical symptoms,enhance the quality of life and relieve side and toxic effects in treatment advanced NSCLC.